Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from TMS Co., Ltd. ( (JP:4891) ).
TMS Co., Ltd. announced that Corxel Pharmaceuticals has enrolled the first patient in the ORION Phase II/III clinical trial for TMS-007 (JX10), an investigational drug for acute cerebral infarction. This global trial aims to evaluate the efficacy and safety of TMS-007, which has shown promising results in previous studies by extending the treatment window for acute ischemic stroke. The trial will enroll approximately 740 participants across 20 countries, potentially impacting the treatment landscape for stroke patients by offering a broader treatment window and improving clinical outcomes.
More about TMS Co., Ltd.
TMS Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to discovering and developing transformative medicines for serious diseases with high unmet medical needs. The company’s pipeline includes small molecule compounds called SMTPs, derived from a fungus, with its lead program, TMS-007 (JX10), showing efficacy and safety in treating acute ischemic stroke. TMS also explores treatments for hypertension, acute kidney injury, and spinal cord injury, leveraging partnerships with academic institutions in Japan to bridge academic discoveries with the global pharmaceutical market.
Average Trading Volume: 1,293,154
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.92B
See more insights into 4891 stock on TipRanks’ Stock Analysis page.